Search

Exelixis Inc

Suletud

SektorTervishoid

53.99 0.6

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

53.48

Max

54.66

Põhinäitajad

By Trading Economics

Sissetulek

1.6M

212M

Müük

18M

629M

P/E

Sektori keskmine

16.453

57.371

Aktsiakasum

0.82

Kasumimarginaal

33.729

Töötajad

1,077

EBITDA

-12M

263M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

-3.99% downside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

3. nov 2026

Turustatistika

By TradingEconomics

Turukapital

-876M

13B

Eelmine avamishind

53.39

Eelmine sulgemishind

53.99

Uudiste sentiment

By Acuity

50%

50%

171 / 340 Pingereas Healthcare

Exelixis Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

21. aug 2026, 20:06 UTC

Exelixis Inc shares are higher today, continuing a trend since Thursday's close. Broader biotechnology sector gains may be contributing to the movement.

20. aug 2026, 23:36 UTC

Exelixis Inc's shares are higher in after-market trading, reflecting notable strength despite no specific news to explain the price action.

19. aug 2026, 19:36 UTC

News

BMO Capital initiated coverage on Exelixis Inc with a Market Perform rating and a price target of $54. Shares are trading higher today.

18. aug 2026, 23:56 UTC

News

Exelixis shares are lower in after-market hours following BMO's Market Perform rating. Broader market pressures from rising bond yields also weigh on the stock.

13. aug 2026, 19:46 UTC

Exelixis Inc's shares are higher Thursday, supported by positive investor sentiment despite a slight pullback from earlier gains. Initial jobless claims rose to 209k.

12. aug 2026, 19:51 UTC

News

Exelixis Inc shares are lower amid an investigation for potential securities law violations and a revenue shortfall of $628.7 million in Q2.

11. aug 2026, 23:51 UTC

Exelixis Inc shares are lower in after-market hours, continuing a downward trend since Tuesday's close amid notable volatility and market anticipation of the CPI report.

10. aug 2026, 23:01 UTC

News

Exelixis shares are lower in after-market trading amid scrutiny over a potential securities fraud investigation and lowered full-year revenue guidance.

8. aug 2026, 00:01 UTC

Exelixis Inc shares are trading lower in after-market hours, amid weak overall market conditions and unusual trading patterns.

7. aug 2026, 21:01 UTC

Exelixis Inc shares are lower in after-market trading, reflecting notable weakness and remaining below the 20-day moving average. No specific news was identified.

6. aug 2026, 23:31 UTC

Exelixis Inc's shares are higher in after-market hours, recovering from an earlier dip. The stock remains below its 20-day moving average.

5. aug 2026, 23:02 UTC

News

Exelixis Inc. shares are lower in after-market trading following second-quarter results that missed revenue expectations and a cut to full-year guidance.

4. aug 2026, 19:16 UTC

Exelixis Inc shares are higher today, reaching a peak above Monday's close. The broader market is supported by a drop in crude oil prices.

3. aug 2026, 23:02 UTC

Exelixis Inc shares are lower in after-market trading, continuing a decline since Monday's close amid no specific news to explain the movement.

31. juuli 2026, 23:36 UTC

Exelixis Inc shares are lower in after-market trading, influenced by broader market weakness amid a decline in Apple shares following disappointing guidance.

30. juuli 2026, 17:56 UTC

Exelixis shares are higher during Thursday's session, gradually improving from an early dip. No specific company news was identified to explain the movement.

29. juuli 2026, 19:37 UTC

Exelixis Inc. shares are trading lower today amid high volume and broader market dynamics, including a significant surge in oil prices raising inflation concerns.

28. juuli 2026, 20:06 UTC

Exelixis Inc is trading higher amid a strong Biotechnology sector. The stock remains above its 20-day moving average, indicating market strength.

27. juuli 2026, 18:46 UTC

Exelixis Inc shares are higher today, reflecting broader market trends amid a notable decline in crude oil prices. The stock peaked earlier in the session.

24. juuli 2026, 19:46 UTC

Exelixis Inc shares are lower today, continuing a decline since Thursday. Broader market volatility is influenced by fluctuations in oil prices and U.S. tariffs.

22. juuli 2026, 21:26 UTC

News

Exelixis Inc will release its Q2 2026 financial results on August 5. Shares are trading higher after the announcement, reflecting positive investor sentiment.

Võrdlus sarnastega

Hinnamuutus

Exelixis Inc Prognoos

Hinnasiht

By TipRanks

-3.99% langus

12 kuu keskmine prognoos

Keskmine 51.92 USD  -3.99%

Kõrge 64 USD

Madal 41 USD

Põhineb 15 Wall Streeti analüütiku instrumendi Exelixis Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

15 ratings

4

Osta

10

Hoia

1

Müü

Sentiment

By Acuity

171 / 340 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Exelixis Inc

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
help-icon Live chat